Core Insights - Warby Parker, a direct-to-consumer eyewear company, reported a significant insider sale by co-CEO David Abraham Gilboa, who sold 94,906 shares valued at $2.61 million [1][2][8] Company Overview - Warby Parker generated $850.58 million in revenue over the trailing twelve months (TTM) and reported a net income of $717,000 [4] - The company's stock price increased by 11.77% over the past year, although it lags behind the S&P 500, which rose approximately 18% during the same period [8] Transaction Details - The insider sale involved the conversion and sale of derivative securities under a pre-established Rule 10b5-1 trading plan, indicating planned monetization rather than opportunistic trading [5][8] - Post-transaction, Gilboa retains 37,247 shares, representing 0.03% of the outstanding shares, while still holding significant exposure through derivative securities [5][8] Operational Performance - Warby Parker's third-quarter revenue increased by 15% year-over-year to $221.7 million, with net income rising to $5.9 million from a loss in the previous year [9] - Adjusted EBITDA reached $25.7 million, resulting in a margin of 11.6%, and the number of active customers grew by over 9% on a trailing twelve-month basis [9] Market Position - The company operates a vertically integrated model, controlling costs and delivering value through both physical stores and online platforms, targeting value-conscious consumers in the U.S. and Canada [6][7]

Shares of Warby Parker Inc. (NYSE:WRBY – Get Free Report) dropped 5.2% during trading on Friday . The company traded as low as $24.84 and last traded at $24.9490. Approximately 300,119 shares changed hands during trading, a decline of 88% from the average daily volume of 2,469,652 shares. The stock had previously closed at $26.33. Get Warby Parker alerts: Wall Street Analysts Forecast GrowthWRBY has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shar ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44 Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 ...

Core Insights - National Vision (EYE) has experienced a significant share price increase of 154.6% over the past 12 months, outperforming the industry decline of 13.9% and the S&P 500's growth of 16.4% [1][9] Company Performance - National Vision holds a Zacks Rank 3 (Hold) and is benefiting from the strong performance of its America's Best brand, with strategic initiatives showing early progress [2] - The company operates 1,242 retail stores across four brands and has a distribution network that includes a 118,000-square-foot center in Georgia and a 52,000-square-foot center in Ohio [3] Revenue Growth - The Owned & Host segment of National Vision reported a 9.1% year-over-year revenue increase in Q3 2025, primarily driven by America's Best brand [4][9] - The company opened four new America's Best stores and converted four Eyeglass World locations during the September 2024 to September 2025 period [5] Strategic Initiatives - National Vision is enhancing its Eyeglass World operations with a new leadership team and expanding remote exam capabilities, with two-thirds of its stores now equipped for remote technology [6] - The company is testing smaller store formats for America's Best and is incorporating insights from a fleet optimization review into future growth plans [5][6] Customer Engagement - Early indicators of stronger customer engagement are noted, supported by a new marketing strategy and customer relationship management (CRM) platform [10] - Newly introduced premium frames are selling faster than expected, indicating positive consumer response [10] Financial Estimates - The Zacks Consensus Estimate projects a 32.6% increase in earnings per share (EPS) for 2025, reaching $0.69, and a 26.8% increase for 2026, reaching $0.88 [12] - Revenues are expected to grow by 5.2% to $1.98 billion in 2025 and reach $2.05 billion in 2026, implying a 3.3% increase [12]

Key Points New York City-based DSC Meridian Capital sold 510,090 shares in Bausch + Lomb during the third quarter. The move marked a full exit from BLCO, with the fund reporting no shares held as of September 30. The net position change was estimated at about $6.6 million. These 10 stocks could mint the next wave of millionaires › New York City-based DSC Meridian Capital fully exited its position in Bausch + Lomb during the third quarter, reducing its holdings by 510,090 shares, a move totaling ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb†or the "company†), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000 tranche (the "Replacement Term Loans†) of new term B loans, the proceeds of which will be used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans†) and its outstanding term B loans due 2028 (the "First Increment ...

With a market cap of $15.8 billion, The Cooper Companies, Inc. (COO) is a global medical device company specializing in contact lenses and women’s health care solutions. Through its CooperVision and CooperSurgical segments, it offers advanced vision-correction lenses as well as fertility, genomics, and contraceptive products. Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Cooper Companies fits this criterion perfectly. The company serves healthcare professionals ...

Have you evaluated the performance of The Cooper Companies' (COO) international operations during the quarter that concluded in October 2025? Considering the extensive worldwide presence of this surgical and contact lens products maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influ ...

One fund just made a bold move on an eye-care giant—here’s why it may signal a deeper shift in the company’s long-term trajectory.Connecticut-based Silver Point Capital initiated a new position in Bausch + Lomb Corporation (BLCO 0.91%), adding nearly 2.6 millino shares for an estimated $38.7 million, per its November 14 SEC filing.What HappenedAccording to a filing with the Securities and Exchange Commission dated November 14, Silver Point Capital disclosed a new stake in Bausch + Lomb Corporation (BLCO 0.9 ...

Core Viewpoint - Alcon is expected to report quarterly earnings of $0.77 per share, a decline of 4.9% year-over-year, with revenues projected at $2.59 billion, reflecting a 6.5% increase compared to the previous year [1] Earnings Projections - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their initial projections [1][2] Key Metrics Forecast - Analysts predict 'Net Sales- Total Surgical' to be $1.42 billion, a 6.1% increase from the prior-year quarter [4] - 'Net Sales- Total Vision Care' is expected to reach $1.17 billion, suggesting a 7.1% year-over-year change [4] Detailed Sales Estimates - 'Net Sales- Total Surgical- Consumables' is estimated at $743.89 million, reflecting a 6.1% increase from the previous year [5] - 'Net Sales- Total Surgical- Equipment/other' is projected at $245.51 million, indicating a 14.2% year-over-year increase [5] - 'Net Sales- Total Vision Care- Contact lenses' is expected to be $724.58 million, a 9.1% increase year-over-year [6] - 'Net Sales- Total Vision Care- Ocular health' is forecasted at $448.60 million, showing a 4.1% change from the prior-year quarter [6] Regional Sales Forecast - 'Net Sales- Total Surgical- Implantables' is projected to reach $430.00 million, a 1.9% increase from the previous year [7] - 'Revenues- Other revenues' are expected to be $19.52 million, indicating a 7.1% decline year-over-year [7] - 'Net sales by region- United States' is forecasted at $1.16 billion, reflecting a 4.6% year-over-year increase [7] - 'Net sales by region- International' is expected to reach $1.43 billion, suggesting an 8.2% increase from the prior-year quarter [8] Stock Performance - Alcon shares have decreased by 2.9% in the past month, contrasting with the Zacks S&P 500 composite's increase of 1.3% [8] - With a Zacks Rank 2 (Buy), Alcon is anticipated to outperform the overall market performance in the near term [8]